The United Kingdom and the United States have concluded a important trade agreement that will ensure no levies on British pharmaceutical shipments entering the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to increase expenditure on pharmaceuticals through the NHS. This commitment guarantees that duties on these key exports will remain at zero for a timeframe of three years.
This development comes after recent warnings to hike duties on branded pharmaceutical imports, with figures floated as high as double the cost.
"This agreement with the Britain reinforces the worldwide climate for innovative medicines and introduces long-overdue balance to American-British drug exports," a release declared.
Economic Significance
Pharmaceuticals are one of the Britain's biggest goods shipped to the United States, which is by far the largest destination for major British pharmaceutical firms.
Trade data reveal that in the one-year period to the end of the third quarter, the UK exported medicines worth over eleven billion pounds to the US. This figure represented a significant portion of all goods exports in that timeframe.
"This guarantee safeguards employment, stimulates capital expenditure and facilitates the UK to establish itself as a global hub for medical research," the Business and Trade Secretary remarked.
Specific NHS Changes
The deal entails several key commitments from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to increase total health service expenditure on drugs from 0.3% of the national economy to 0.6% over the next decade.
- Payback Limit: The percentage drug companies must return to the NHS to control costs will be capped at fifteen percent. Last year, rebates topped 20%.
Recent Tensions
This agreement follows a long-running tension between the drug companies and the British authorities over spending levels and NHS adoption.
This friction were heightened by claims that American consumers were paying significantly more for the equivalent treatments than consumers in the Britain and the EU.
Recently, several major drug company projects in the UK have been paused or cancelled, while multi-billion-dollar expansions have been announced toward American operations.
The Science Minister publicly accepted that the NHS needed to invest a greater share on medicines, noting that its budget allocation on drugs had declined as a share of its total funding over the previous ten-year period.
